BioSpace News Archive

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of shares of its common stock at a purchase price of $2.50 per share in a registered direct offering for gross proceeds of approximately $9 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about Au

Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), is pleased to announce that further to its announcement on August 4, 2020 regarding the development of a medical solution utilizing nanobody technology for COVID-19, it has just signed an agreement with GenScript Biotech Corporation (HKSE: 1548)

Ceek Women’s Health, a groundbreaking women-led medical device company, is excited to announce its latest innovation, the Nella NuSpec Reusable Vaginal Speculum.

Research to prioritize disinfection of high touch surfaces such as subway seat fabric and escalator handrail belts

Kavingali, Corp. announces the opening of its new corporate headquarters.

INSPIRE Phase 3 trial survival events reached Topline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET NEWTOWN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today reported financial results for the quarter ended June 30, 2020, and pr

Inspire Medical Systems, Inc., announced that the Australian Therapeutic Goods Administration has approved Inspire therapy to treat moderate to severe OSA in patients who are unable to benefit from continuous positive airway pressure.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended June 30, 2020. Second Quarter and Recent Business Updates On April 30, 2020, the Company announced that its registrational clinical trial, TBI-001, was published on April 29, 2020 in Neuromodulation: Technology at the Neural Interface . The TBI-

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Corporate and Regulatory Highlights: Received Day-74 Letter for KP415 NDA; FDA has set PDUFA date of March 2, 2021 Announced that Corium, Inc., a portfolio company of GPC, will lead all commercialization activities for KP415 Announced issuance of two additional U.S. patents governing KP415 and KP484 Financial Highlights Reported Q2 2020 revenue of $6.9 million, including $5 million m

--Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer-- --Aldafermin continues to advance toward late-stage clinical development in non-alcoholic steatohepatitis (NASH) with ongoing Phase 2b ALPINE 2/3 and ALPINE 4 clinical studies-- --Initiated Phase 2 CATALINA study of NGM621, a complement C3 inhibitory antibody to treat patients with geographic atrophy (GA)-- --$312.1 million in cash, cash equivalents and marketable